Page 215 - 2019_01-Haematologica-web

HLA-DP-restricted cell-lineage recognition patterns
For example, the current procedure could be optimized by including a depletion step to remove not only auto-reac- tive T cells but also T cells reactive against non- hematopoietic tissue. Although the use of HLA-DP-mis- matched DC from patients will give a range of antigen specificities, including specificities against polymorphic antigens, the dependency on sufficient material from patients to generate CD14-derived DC restricts applicabil- ity. Therefore, the sophisticated approach of Herr and col- leagues, who used autoDC transfected with allo-HLA-DP- encoding RNA as stimulator cells, shows an alternative
way of provoking allo-HLA-DP-restricted donor T cells with different tissue specificities.43 Another strategy to obtain a hematopoiesis-specific T-cell product is to isolate HLA-DP-restricted T-cell receptors from our T-cell clones that showed a more hematopoiesis-specific or myeloid- lineage-specific recognition profile and perform T-cell receptor gene transfer.
Acknowledgments
The research in this manuscript was financially supported by the Dutch Cancer Society (project UL 2013-5989).
References
1. Miller JS, Warren EH, van den Brink MR, et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: graft-versus- tumor/leukemia reaction. Biol Blood Marrow Transplant. 2010;16(5):565-586.
2. vondemBornePA,StarrenburgCW,Halkes SJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag'). Curr Opin Oncol. 2009;21 (Suppl 1): S27-29.
3. Falkenburg JH, Jedema I. Allo-reactive T cells for the treatment of hematological malignancies. Mol Oncol. 2015;9(10):1894- 1903.
4. Barge RM, Osanto S, Marijt WA, et al. Minimal GVHD following in-vitro T cell- depleted allogeneic stem cell transplantation with reduced-intensity conditioning allow- ing subsequent infusions of donor lympho- cytes in patients with hematological malig- nancies and solid tumors. Exp Hematol. 2003;31(10):865-872.
5. Barrett AJ. Mechanisms of the graft-versus- leukemia reaction. Stem Cells. 1997;15(4): 248-258.
6. Falkenburg JH, Warren EH. Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S33-38.
7. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.
8. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383.
9. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17(3):153-162.
10. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373 (9674):1550-1561.
11. Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experi- mental systems instructing clinical practice. Blood. 2014;124(3):354-362.
12. Nash RA, Storb R. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol. 1996;8(5):674-680.
13. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long- term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden expe- rience. Bone Marrow Transplant. 2006;37(12):1129-1134.
14. Falkenburg JHF, Jedema I. Graft versus tumor effects and why people relapse. Hematology Am Soc Hematol Educ Program. 2017;2017(1):693-698.
15. Eefting M, de Wreede LC, Halkes CJM, et al. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. Haematologica. 2016;101(4):506-514.
16. Eefting M, Halkes CJ, de Wreede LC, et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lympho- cyte infusion is an efficient and safe post- remission treatment for adult ALL. Bone Marrow Transplant. 2014;49(2):287-291.
17. Yun HD, Waller EK. Finding the sweet spot for donor lymphocyte infusions. Biol Blood Marrow Transplant. 2013;19(4):507-508.
18. Fernandez-Vina MA, Klein JP, Haagenson M, et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013;121(22):4603-4610.
19. Moreau P, Cesbron A. HLA-DP and allo- geneic bone marrow transplantation. Bone Marrow Transplant. 1994;13(6):675-681.
20. Petersdorf EW, Smith AG, Mickelson EM, et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host dis- ease following unrelated donor marrow transplantation. Blood. 1993;81(7):1923- 1932.
21. van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, et al. Selective graft-versus- leukemia depends on magnitude and diver- sity of the alloreactive T cell response. J Clin Invest. 2017;127(2):517-529.
22. Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, et al. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-ver- sus-leukemia reactivity in the presence or absence of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(1):40-48.
23. Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood. 2013;122(11):1963-1973.
24. Rutten CE, van Luxemburg-Heijs SA, Griffioen M, et al. HLA-DP as specific target
for cellular immunotherapy in HLA class II- expressing B-cell leukemia. Leukemia. 2008;22(7):1387-1394.
25. Petersdorf EW, Malkki M, O'HUigin C, et al. High HLA-DP expression and graft-versus- host disease. N Engl J Med. 2015;373 (7):599-609.
26. Fleischhauer K, Beelen DW. HLA mismatch- ing as a strategy to reduce relapse after alter- native donor transplantation. Semin Hematol. 2016;53(2):57-64.
27. Cesbron A, Moreau P, Cheneau ML, et al. Crucial role of the third and fourth hyper- variable regions of HLA-DPB1 allelic sequences in primary mixed-lymphocyte reaction: application in allogeneic bone mar- row transplantation. Transplant Proc. 1993;25(1 Pt 2):1232-1233.
28. Nicholson I, Varney M, Kanaan C, et al. Alloresponses to HLA-DP detected in the primary MLR: correlation with a single amino acid difference. Hum Immunol. 1997;55(2):163-169.
29. Zino E, Frumento G, Marktel S, et al. A T- cell epitope encoded by a subset of HLA- DPB1 alleles determines nonpermissive mis- matches for hematologic stem cell trans- plantation. Blood. 2004;103(4):1417-1424.
30. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermis- sive HLA-DPB1 disparity in host-versus- graft direction. Blood. 2006;107(7):2984- 2992.
31. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA- DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retro- spective study. Lancet Oncol. 2012;13(4): 366-374.
32. Fleischhauer K, Shaw BE. HLA-DP in unre- lated hematopoietic cell transplantation revisited: challenges and opportunities. Blood. 2017;130(9):1089-1096.
33. Ni K, O'Neill HC. The role of dendritic cells in T cell activation. Immunol Cell Biol. 1997;75(3):223-230.
34. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for anti- gen-presenting cells and alloantigen expres- sion in graft-versus-leukemia responses. Nat Med. 2005;11(11):1244-1249.
35. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352.
36. Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH. Successful generation of primary virus-spe- cific and anti-tumor T-cell responses from the naive donor T-cell repertoire is deter- mined by the balance between antigen-spe-
haematologica | 2019; 104(1)
205